Five Prime Therapeutics Five Prime Therapeutics Latest from The Business Journals QB3 spotlights University of California science, 'American Idol'-style150 Most Influential Women in Bay Area business namedFivePrime, Dyax enter antibody R&D deal Follow this company founder Lewis “Rusty” Williams has replaced Julia Gregory as CEO, Elsevier Inc.’s In Vivo Blog reported.
A Five Prime spokeswoman confirmed that Gregory is no longer with the company, the blog reported. A Five Prime spokeswoman did not return a phone message left by the San Francisco Business Times.
Gregory replaced Gail Maderis as CEO in 2009, coming from Lexicon Pharmaceuticals. During her tenure, the antibody drug development company signed a potential $500 million licensing deal with Human Genome Sciences that included a $50 million upfront payment.
Gregory also moved the privately held company from San Francisco’s Mission Bay biotech enclave to South San Francisco and was largely expected to help the company raise its profile with investment bankers. At Lexicon, she led finance and business development.
